Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review.
Antivir Ther
; 28(1): 13596535231159030, 2023 02.
Article
in En
| MEDLINE
| ID: mdl-36802921
ABSTRACT
Background:
Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials. However, studies on real-world evidence on its efficacy, safety and tolerability are limited.Purpose:
The study aims to collate real-world evidence on the use of Biktarvy in clinical practice to identify gaps in knowledge. ResearchDesign:
Scoping review was undertaken using PRISMA guidelines and a systematic search strategy. The final search strategy used was (Bictegravir* OR biktarvy) AND (efficac* OR safe* OR effect* OR tolerab* OR 'side effect*' OR 'adverse effect*'). The last search was performed on the 12th of August 2021. Study Sample Studies were eligible if they reported on the efficacy, effectiveness, safety or tolerability of bictegravir-based ART. Data Collection and/orAnalysis:
Data were collected from 17 studies that met the inclusion and exclusion criteria and summarised using a narrative synthesis.Results:
The efficacy of Biktarvy in clinical practice is comparable to phase III trials. However, adverse effects and discontinuation rates were found to be higher in real-world studies.Conclusions:
The cohorts in the included real-world studies showed more demographic diversity when compared to the drug approval trials, further prospective studies are required on under-represented groups such as women, pregnant people, ethnic minorities and older adults.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
Type of study:
Guideline
/
Observational_studies
/
Prognostic_studies
/
Systematic_reviews
Limits:
Aged
/
Female
/
Humans
/
Pregnancy
Language:
En
Journal:
Antivir Ther
Journal subject:
TERAPIA POR MEDICAMENTOS
/
VIROLOGIA
Year:
2023
Document type:
Article
Affiliation country:
United kingdom